US 11,707,525 B2
Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
Abraham Pinter, Brooklyn, NY (US); and Alok K. Choudhary, Newark, NJ (US)
Assigned to RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ (US)
Filed by Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed on Feb. 17, 2022, as Appl. No. 17/651,523.
Application 16/910,621 is a division of application No. 16/076,971, granted, now 10,729,771, issued on Aug. 4, 2020, previously published as PCT/US2017/016058, filed on Feb. 1, 2017.
Application 17/651,523 is a continuation of application No. 16/910,621, filed on Jun. 24, 2020, granted, now 11,273,220.
Claims priority of provisional application 62/293,406, filed on Feb. 10, 2016.
Prior Publication US 2022/0168420 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/40 (2006.01); C07K 16/12 (2006.01); G01N 33/569 (2006.01); A61P 31/06 (2006.01); A61K 39/04 (2006.01)
CPC A61K 39/40 (2013.01) [A61K 39/04 (2013.01); A61P 31/06 (2018.01); C07K 16/1289 (2013.01); G01N 33/5695 (2013.01); G01N 33/56933 (2013.01); C07K 2317/21 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); G01N 2333/35 (2013.01); G01N 2400/02 (2013.01); G01N 2800/44 (2013.01)] 9 Claims
 
1. A monoclonal anti-lipoarabinomannan (anti-LAM) antibody, Or an antigen-binding portion thereof, that specifically binds to a LAM epitope comprising an Ara4 structure, an Ara6 structure, or a combination thereof, wherein the anti-LAM antibody comprises a CDR1 light chain variable region having at least 80% identity with SEQ ID NO: 1 or antigenic fragments thereof, a CDR2 light chain variable region having at least 80% identity with SEQ ID NO: 2 or antigenic fragments thereof, a CDR3 light chain variable region having at least 80% identity with SEQ ID NO: 3 or SEQ ID NO: 26 or antigenic fragments thereof, a CDR1 heavy chain variable region having at least 80% identity with SEQ ID NO: 4 or antigenic fragments thereof, a CDR2 heavy chain variable region having at least 80% identity with SEQ ID NO: 5 or antigenic fragments thereof, and a CDR3 heavy chain variable region having at least 80% identity with SEQ ID NO: 6 or SEQ ID NO: 23 or antigenic fragments thereof, having a modified heavy chain constant region.